Please login to the form below

Not currently logged in

Aurobindo joins Patent Pool

Aurobindo Pharma has become the first generics manufacturer to join the Medicines Patent Pool for the manufacture of HIV/AIDS treatments

Aurobindo Pharma has become the first generics manufacturer to join the Medicines Patent Pool for the manufacture of HIV/AIDS treatments.

The agreement will enable Aurobindo to manufacture products licensed to the Pool by Gilead Sciences in July: emtricitabine, cobicistat, elvitegravir, and the fixed-dose combination of these medicines known as the Quad (a combination of the three drugs and tenofovir).

The Pool said generic manufacturers choosing to develop and manufacture these treatments will help close the gap between the arrival of new medical technology in developed country markets and its often delayed arrival in developing countries.

Aurobindo has chosen not to take a licence on tenofovir, on which there is currently no product patent in India, meaning the company does not have to pay royalties on the product.

The Medicines Patent Pool, founded with the support of UNITAID in 2010, aims to bring down the prices of HIV medicines, and stimulate the development of needed new formulations, through access-oriented voluntary licences.

The Pool's voluntary licences are negotiated to maximise their public health impact.

PV Ramaprasad Reddy, chairman of Aurobindo, said: "We are excited about both the public health and business opportunities provided by the Patent Pool licences. Aurobindo looks forward to increasing its manufacture of HIV-related products, and expanding its work to cover promising new treatments, for the millions of people living with HIV across the globe."

12th October 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...